Recurrent SARS-CoV-2 Infection and Impaired Immunologic Response in a Pediatric Oncologic Patient While Treated With Radiochemotherapy.

Autor: Eichholz T; From the University Children's Hospital, Eberhard Karls University, Tuebingen, Germany., Arendt AM; From the University Children's Hospital, Eberhard Karls University, Tuebingen, Germany., Holzer U; From the University Children's Hospital, Eberhard Karls University, Tuebingen, Germany., Seitz C; From the University Children's Hospital, Eberhard Karls University, Tuebingen, Germany., Rabsteyn A; From the University Children's Hospital, Eberhard Karls University, Tuebingen, Germany., Ganzenmueller T; Institute for Medical Virology and Epidemiology of Viral Diseases, Eberhard Karls University, Tuebingen, Germany., Klein R; Department of Internal Medicine II, Hematology/Oncology, Eberhard Karls University, Tuebingen, Germany., Walz J; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, Tuebingen, Germany., Lang P; From the University Children's Hospital, Eberhard Karls University, Tuebingen, Germany.
Jazyk: angličtina
Zdroj: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2022 Jun 01; Vol. 41 (6), pp. e259-e262. Date of Electronic Publication: 2022 May 06.
DOI: 10.1097/INF.0000000000003515
Abstrakt: Immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pediatric patients with malignant disease may be affected by tumor therapy. Here, we report the case of a child with rhabdomyosarcoma and recurrent SARS-CoV-2 infection. Immunologic responses, analyzed by T-cell activity and anti-viral IgG levels, were impaired and not durable as a result of intensive radiochemotherapy.
Competing Interests: J.W. is listed as inventor for patents on peptides described in this manuscript. The other authors have no conflicts of interest to disclose.
(Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze: MEDLINE
Externí odkaz: